In a patient with AIDS who is on apixaban (Eliquis), should I obtain a bedside abdominal ultrasound first or proceed directly to paracentesis?

Obtain Bedside Ultrasound First Before Paracentesis in AIDS Patients on Eliquis

In an AIDS patient on apixaban (Eliquis) requiring paracentesis, you should perform a bedside abdominal ultrasound first to confirm adequate ascites and guide safe needle placement, then proceed with the paracentesis without routinely interrupting the anticoagulant.

Ultrasound Guidance is Essential

Ultrasound guidance should be considered when available during paracentesis to reduce the risk of adverse events 1. This recommendation is particularly critical in your scenario for several reasons:

• Confirms adequate fluid volume: In AIDS patients, ascites may be less abundant or loculated. Ultrasound identifies the optimal pocket of fluid and prevents dry taps 2, 3
• Identifies anatomical hazards: Ultrasound visualizes bowel loops, enlarged organs (liver/spleen), and vascular structures that could be injured during blind needle insertion 2
• Improves success rates: Studies demonstrate ultrasound-guided paracentesis has superior safety profiles and lower failure rates compared to physical examination alone 2, 4

The left lower quadrant typically offers the thinnest abdominal wall and greatest ascites depth, with puncture sites recommended at least 8 cm from midline and 5 cm above the symphysis to avoid the inferior epigastric artery 1.

Managing Eliquis (Apixaban) During the Procedure

Do NOT Routinely Hold Anticoagulation

Routine measurement of prothrombin time and platelet count before therapeutic or diagnostic paracentesis and infusion of blood products are not recommended 1. This strong recommendation extends to patients on direct oral anticoagulants like apixaban.

Key Safety Considerations with Apixaban:

• Timing matters significantly: Avoid performing paracentesis within 6 hours of the last apixaban dose, as this peak concentration period carries the highest bleeding risk 5
• Standard dosing (5 mg twice daily) appears safer: High-dose apixaban (10 mg twice daily) was associated with 38% bleeding rate versus much lower rates at standard dosing 5
• Avoid polypharmacy: Co-prescription of apixaban with additional antiplatelet or anticoagulant agents dramatically increases hemorrhage risk (19% bleeding rate) 5

When to Consider Holding Apixaban:

According to FDA labeling, Eliquis should be discontinued at least 24 hours prior to elective procedures with low bleeding risk 6. However, paracentesis falls into a nuanced category:

• Recent evidence shows uninterrupted therapeutic anticoagulation during paracentesis appears safe with low bleeding complication rates (0-1.4%) when ultrasound guidance is used 7, 8
• The 2025 French guidelines suggest measuring DOAC concentration before high-bleeding-risk procedures, with a safety threshold of 50 ng/mL (30 ng/mL for highest-risk procedures) 9

Practical Algorithm:

1. If last apixaban dose was >12 hours ago (ideally >24 hours): Proceed with ultrasound-guided paracentesis
2. If last dose was <6 hours ago: Delay procedure if clinically feasible
3. If patient is on 10 mg twice daily or multiple anticoagulants: Consider holding one dose and waiting 12-24 hours
4. If procedure cannot be delayed: Use real-time ultrasound guidance (not just skin marking) and ensure experienced operator

AIDS-Specific Considerations

AIDS patients may have atypical presentations and multiple potential causes of ascites beyond cirrhosis 10. The ultrasound serves dual purposes:

• Diagnostic evaluation: Identifies lymphadenopathy, hepatosplenomegaly, or other HIV-related pathology 10
• Guides fluid analysis: Ensures adequate sample for cell count, culture (inoculate 10 ml into blood culture bottles), albumin, and protein 1, 11

Critical Pitfalls to Avoid

1. Do not rely on skin marking alone: Studies show only 5-14% success rates when ultrasound is used solely for marking rather than real-time guidance 3
2. Do not perform blind paracentesis in anticoagulated patients: The combination of anticoagulation and blind technique substantially increases hemorrhage risk 5, 2
3. Do not assume coagulopathy requires correction: Fresh frozen plasma and platelet transfusions before paracentesis are not recommended even with abnormal INR or thrombocytopenia, unless there is active DIC or fibrinolysis 1, 12, 13
4. Do not restart apixaban immediately post-procedure: Wait until adequate hemostasis is established 6

Post-Procedure Monitoring

After paracentesis in anticoagulated patients:

• Monitor puncture site for 2 hours
• Have patient lie on opposite side if any leakage occurs 1
• Consider purse-string suture if persistent leakage 1
• Resume apixaban only after confirming hemostasis 6